Device Startups and Alliances: Between a Rock and a Hard Place
Development’s more expensive, markets are smaller, investors are meaner. But alliances aren’t the answer. Or at least not the answer anyone wants to hear. It's time to rethink the anti-alliance logic, which may require a new approach to starting up device companies.
You may also be interested in...
At ESMO, data showed overall response benefit in combination with carboplatin in first-line therapy, and with Keytruda in second- or third-line treatment. The antibody-drug conjugate obtained US approval on 20 September as monotherapy.
Portico with the FlexNav delivery system earned FDA approval for people with symptomatic, severe aortic stenosis who would be at high or extreme risk in open-heart surgery.
The companies announced data from their Phase II/III study in children aged 5-11 and intend to take them to regulators to expand Comirnaty's authorization; also, an expert panel advising India's drug regulator endorsed plans for a Phase III trial of a single-dose Russian vaccine, Sputnik Light.